Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel

The global palmoplantar pustulosis market is experiencing steady growth driven by increased awareness, diagnosis rates, and development of targeted biologic therapies. Key advances in IL-23 and IL-36 research, precision medicine, and AI-assisted diagnostics are accelerating treatment development. While topical therapies remain central for mild cases, systemic agents and biologics are supporting moderate-to-severe disease management. Growth is reinforced by clinical trials and regulatory approvals across North America, Europe, and Asia-Pacific, though high treatment costs and limited access in developing regions remain challenges.